Abstract
Systematic functional evidence is lacking for most rare GBA1 variants, limiting their interpretation in Gaucher disease (GD) and Parkinson’s disease (PD). Here, we used a multiplexed assay of variant effect (MAVE) to generate a comprehensive atlas of lysosome-specific glucocerebrosidase (GCase) activity for more than 10,400 GBA1 variants, covering 97% of all possible single-amino-acid substitutions. The atlas recapitulated known structural and biochemical determinants of glucocerebrosidase function and revealed concordance between functional impairment and expert-curated pathogenicity classifications. It identified significantly reduced activity in 94 of 186 reported variants of uncertain significance and revealed a quantitative relationship between functional impairment and GD disease severity. Integration with the Global Parkinson’s Genetics Program associated greater variant-level functional impairment with earlier PD onset and higher PD odds ratios. Independent measurements of lysosomal glucocerebrosidase activity in stable cell lines expressing individual variants validated the MAVE results and resolved subtle functional deficits among variants close to the wild-type range, including established PD risk alleles. These findings provide a functional reference framework linking GBA1 variants to their molecular consequences and clinical phenotypes and demonstrate how comprehensive variant-effect maps can inform genetic interpretation and precision medicine.
Funding Information
  • Michael J. Fox Foundation (024896)
  • Medical Research Council (MC_UU_00038/1)
  • Aligning Science Across Parkinson's (ASAP-000463)
  • Aligning Science Across Parkinson's (ASAP-027054)

This publication has 59 references indexed in Scilit: